Fei Fei Liu
About Fei Fei Liu
Fei Fei Liu is the Director of Worldwide Health Economics and Outcomes Research for CAR T at Bristol Myers Squibb, with extensive experience in oncology and hematology research.
Title
Fei Fei Liu holds the position of Director, Worldwide Health Economics and Outcomes Research, CAR T at Bristol Myers Squibb.
Current Role at Bristol Myers Squibb
Fei Fei Liu is currently employed at Bristol Myers Squibb as the Director of Worldwide Health Economics and Outcomes Research, focusing on CAR T therapies. She leads the development of health economics and outcomes research strategies for CAR T therapies, contributing to the company's leadership in this innovative treatment area.
Previous Experience at Bristol Myers Squibb
Fei Fei Liu served as Associate Director, Worldwide Health Economics and Outcomes Research (HEOR), CAR T, at Bristol Myers Squibb from 2019 to 2021. During this period, she was stationed in Summit, New Jersey, and was involved in the development and execution of economic models to support drug pricing and access strategies for CAR T therapies.
Past Roles at Celgene
Fei Fei Liu has extensive experience from her tenure at Celgene, where she held multiple positions. She was Associate Director, Global Health Economics and Outcomes Research CAR T in 2019 for 6 months, and prior to that, she served as Senior Manager, Health Economics and Outcome Research (2017-2019), and Senior Manager, Pricing and Reimbursement (Immunology) (2013-2017). These roles were based in Summit, New Jersey, and Toronto, Ontario.
Education and Academic Background
Fei Fei Liu is academically accomplished with an MBA from The University of British Columbia (2004-2006), a B.S. from Kaohsiung Medical University (1994-1998), and a Graduate Diploma from McMaster University. Her educational background has fortified her expertise in health economics and outcomes research, allowing her to excel in her professional roles.
Skills in Real-World Evidence (RWE) Development
Fei Fei Liu has a robust background in real-world evidence (RWE) development, with a concentration in oncology and hematology. This experience supports her capability to generate and interpret data that informs product lifecycle management, patient-reported outcomes measures, and strategic decision-making in clinical and commercial contexts.
Experience at Eli Lilly Canada
From 2001 to 2011, Fei Fei Liu held various roles at Eli Lilly Canada, including Clinical Research Associate, Medical Liaison, Senior Clinical Research Associate, Government and Economic Affairs Associate, and Financial Analyst. Her early career at Eli Lilly encompassing roles in Taipei City, Taiwan, and Canada provided her with foundational industry experience. She contributed across domains such as clinical research, financial analysis, and government affairs.